APA

Park J., Finn R. S., Kim J. S., Karwal M., Li R. K., Ismail F., Thomas M., Harris R., Baudelet C., Walters I. & Raoul J. (20110721). Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Chicago

Park Joong-Won, Finn Richard S, Kim Jun Suk, Karwal Mark, Li Ruby K, Ismail Fuad, Thomas Melanie, Harris Rosemarie, Baudelet Christine, Walters Ian and Raoul Jean-Luc. 20110721. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Harvard

Park J., Finn R. S., Kim J. S., Karwal M., Li R. K., Ismail F., Thomas M., Harris R., Baudelet C., Walters I. and Raoul J. (20110721). Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. : Clinical cancer research : an official journal of the American Association for Cancer Research.

MLA

Park Joong-Won, Finn Richard S, Kim Jun Suk, Karwal Mark, Li Ruby K, Ismail Fuad, Thomas Melanie, Harris Rosemarie, Baudelet Christine, Walters Ian and Raoul Jean-Luc. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. : Clinical cancer research : an official journal of the American Association for Cancer Research. 20110721.